Anacor Pharmaceuticals Inc (ANAC1)

Sector:
HEALTH CARE
Industry:
HEALTH CARE
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Paul L. Berns
Employees:
110
1020 E. MEADOW CIRCLE, PALO ALTO, CA 94303
650-543-7500

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Anacor Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform.

Data derived from most recent annual or quarterly report
Market Cap 4.45 Billion Shares Outstanding44.86 Million Avg 30-day Volume 3.402 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-1.45
Price to Revenue28.6538 Debt to Equity1.3948 EBITDA-54.16 Million
Price to Book Value54.3886 Operating Margin-70.3105 Enterprise Value2.349 Billion
Current Ratio6.289 EPS Growth0.216 Quick Ratio6.02
1 Yr BETA 1.6597 52-week High/Low 0.0 / Profit Margin-76.1397
Operating Cash Flow Growth-436.6692 Altman Z-Score9.9569 Free Cash Flow to Firm -71.898 Million
View SEC Filings from ANAC1 instead.

View recent insider trading info

Funds Holding ANAC1 (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ANAC1 BETA

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Events (8k)

  • 8-K: filed on 2016-06-24:
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 2.04: Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.01: Changes in Control of Registrant
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2016-06-08:
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2016-05-16:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2016-05-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2016-04-06:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
    Item 3.02: Unregistered Sales of Equity Securities
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2016-04-01:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2016-03-30:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2016-03-22:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2016-02-29:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2016-02-24:
    Item 8.01: Other Events
  • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    GLAZER CAPITAL, LLC

    GLAZER PAUL J

    • 10% Owner
    2,968,202 2021-02-23 0

    COLLINS TOMAGO

    • Director
    0 2021-02-22 0

    GUTIERREZ XAVIER A

    • Director
    0 2021-02-22 0

    ARCTOS NORTHSTAR ACQUISITION HOLDINGS, LLC

    • 10% Owner
    0 2021-02-22 0

    SMITH JARED T

    • Director
    0 2021-02-22 0

    EPSTEIN THEO NATHANIEL SEE REMARKS

    • Officer
    • Director
    0 2021-02-22 0

    MCPHERRON MEREDITH LAZO

    • Director
    0 2021-02-22 0

    CHARLES IAN HUNTER

    • Director
    • 10% Owner
    0 2021-02-22 0

    VEDRO JOHN BARNEY CHIEF FINANCIAL OFFICER

    • Officer
    0 2021-02-22 0

    OCONNOR DAVID JUSTIN SEE REMARKS

    • Officer
    • Director
    • 10% Owner
    0 2021-02-22 0

    LESCHLY MARK

    • Director
    No longer subject to file 2016-06-24 0

    RIEFLIN WILLIAM JL

    • Director
    No longer subject to file 2016-06-24 0

    BERNS PAUL L PRESIDENT AND CEO

    • Officer
    • Director
    No longer subject to file 2016-06-24 0

    WIERENGA WENDALL

    • Director
    No longer subject to file 2016-06-24 0

    HOVE ANDERS D

    • Director
    No longer subject to file 2016-06-24 0

    LEONARD KEITH R

    • Director
    No longer subject to file 2016-06-24 0

    IPPOLITO VINCENT P EVP & CHIEF COMMERCIAL OFFICER

    • Officer
    No longer subject to file 2016-06-24 0

    SHAPIRO LUCY

    • Director
    No longer subject to file 2016-06-24 0

    ZANE LEE SVP AND CHIEF MEDICAL OFFICER

    • Officer
    No longer subject to file 2016-06-24 0

    SULLIVAN RYAN T EVP AND GENERAL COUNSEL

    • Officer
    No longer subject to file 2016-06-24 0

    BELL GRAEME EXECUTIVE VP AND CFO

    • Officer
    No longer subject to file 2016-06-24 0

    MAPLES KIRK R SVP, PROGRAM MANAGEMENT

    • Officer
    7,220 2015-06-01 0

    PLATTNER JACOB J SENIOR VP, RESEARCH

    • Officer
    22,860 2015-05-15 0

    RODRIGUEZ CARMEN R SNR VP REG AFRS & QUAL. ASSUR.

    • Officer
    7,020 2015-05-12 0

    CHANDA SANJAY SVP, DRUG DEVELOPMENT

    • Officer
    29,087 2015-03-04 0

    PARKER GEOFFREY M. EXECUTIVE VICE PRESIDENT & CFO

    • Officer
    274,840 2015-02-03 0

    KLINGENSTEIN PAUL H

    • Director
    0 2014-05-29 0

    PERRY DAVID P PRESIDENT AND CEO

    • Officer
    • Director
    361,306 2014-03-04 0

    RHO VENTURES IV QP LP

    RHO VENTURES IV GMBH & CO BETEILIGUNGS KG

    RHO VENTURES IV HOLDINGS LLC

    RHO VENTURES IV LP

    RHO MANAGEMENT VENTURES IV LLC

    • 10% Owner
    No longer subject to file 2014-02-03 0

    VENROCK ASSOCIATES IV L P

    VENROCK PARTNERS, L.P.

    VENROCK ENTREPRENEURS FUND IV L P

    VENROCK MANAGEMENT IV, LLC

    VENROCK PARTNERS MANAGEMENT, LLC

    VEF MANAGEMENT IV, LLC

    VENROCK HEALTHCARE CAPITAL PARTNERS LP

    VHCP CO-INVESTMENT HOLDINGS, LLC

    VHCP MANAGEMENT, LLC

    ROBERTS BRYAN E

    • 10% Owner
    3,575,535 2013-11-15 0

    RHO VENTURES IV LP

    • 10% Owner
    243,815 2013-11-14 0

    RHO VENTURES IV QP LP

    RHO VENTURES IV HOLDINGS LLC

    RHO VENTURES IV GMBH & CO BETEILIGUNGS KG

    RHO VENTURES IV LP

    RHO CAPITAL PARTNERS VERWALTUNGS GMBH

    RHO MANAGEMENT VENTURES IV LLC

    • 10% Owner
    4,371,423 2013-10-24 0

    VENROCK ASSOCIATES V LP

    VENROCK PARTNERS V L P

    VENROCK MANAGEMENT V, LLC

    VENROCK PARTNERS MANAGEMENT V, LLC

    ROBERTS BRYAN E

    • 10% Owner
    3,725,535 2012-09-20 0

    VENROCK ASSOCIATES IV L P

    VENROCK PARTNERS, L.P.

    VENROCK ENTREPRENEURS FUND IV L P

    VENROCK MANAGEMENT IV, LLC

    VENROCK PARTNERS MANAGEMENT, LLC

    VEF MANAGEMENT IV, LLC

    VENROCK HEALTHCARE CAPITAL PARTNERS LP

    VHCP CO-INVESTMENT HOLDINGS, LLC

    VHCP MANAGEMENT, LLC

    • 10% Owner
    3,725,535 2012-09-20 0

    HEYMAN IRWIN A SENIOR VP, DRUG DEVELOPMENT

    • Officer
    0 2012-03-13 0

    RHO MANAGEMENT TRUST I

    • 10% Owner
    0 2011-12-20 0

    RHO VENTURES IV HOLDINGS LLC

    • 10% Owner
    1,533,600 2011-12-20 0

    MARKHAM RICHARD J

    • Director
    0 2011-05-25 0

    CARE CAPITAL INVESTMENTS II LP

    CARE CAPITAL OFFSHORE INVESTMENTS II LP

    • 10% Owner
    No longer subject to file 2010-11-30 0

    VENROCK HEALTHCARE CAPITAL PARTNERS LP

    VHCP CO-INVESTMENT HOLDINGS, LLC

    VHCP MANAGEMENT, LLC

    ROBERTS BRYAN E

    • SEE FOOTNOTE 2SEE FOOTNOTE 2SEE FOOTNOTE 2SEE FOOTNOTE 2
    2,000,000 2010-11-30 0

    RHO VENTURES IV QP LP

    RHO VENTURES IV LP

    RHO MANAGEMENT TRUST I

    RHO VENTURES IV GMBH & CO BETEILIGUNGS KG

    RHO CAPITAL PARTNERS VERWALTUNGS GMBH

    RHO MANAGEMENT VENTURES IV LLC

    RUCH JOSHUA

    RHO CAPITAL PARTNERS INC

    KAIROUZ HABIB

    • 10% Owner
    0 2010-11-23 0

    GLAXOSMITHKLINE PLC

    • 10% Owner
    1,771,374 2010-11-23 0

    VENROCK ASSOCIATES IV L P

    VENROCK PARTNERS, L.P.

    VENROCK ENTREPRENEURS FUND IV L P

    VENROCK MANAGEMENT IV, LLC

    VENROCK PARTNERS MANAGEMENT, LLC

    VEF MANAGEMENT IV, LLC

    • 10% Owner
    0 2010-11-23 0

    ABERDARE VENTURES II, L.P.

    ABERDARE VENTURES II (BERMUDA), L.P.

    ABERDARE II ANNEX FUND L P

    ABERDARE GP II, L.L.C.

    • 10% Owner
    0 2010-11-23 0

    HONG ZHI

    • Director
    0 2010-11-23 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    Elevate your investments